NMC Health founder BR Shetty faces $5.4bn fraud trial, largest in UAE healthcare history

The criminal fraud trial of Bavaguthu Raghuram Shetty, founder of NMC Health, opened in Abu Dhabi this week. Prosecutors allege Shetty orchestrated a $5.4 billion fraud that destroyed the UAE's largest private healthcare company and wiped out thousands of investors on the London Stock Exchange.

The case is the biggest corporate fraud prosecution in UAE history. It arrives six years after US short-seller Muddy Waters Research published a report in December 2019 questioning NMC's reported cash balances, triggering a chain of disclosures that revealed the company carried roughly $6.6 billion in debt against the $2 billion it had disclosed to markets.

What NMC operated at its peak

At its height, NMC Health ran over 200 healthcare facilities across 19 countries, with the core of its business in the UAE. Its Abu Dhabi hospitals, including NMC Royal Hospital, Brightpoint Royal Hospital, and the NMC ProVita long-term care network, made it the dominant private operator in the emirate. It was the first Abu Dhabi-based company listed on the FTSE 100.

The prosecution's case rests on several categories of alleged misconduct:

• Systematic inflation of cash balances on financial statements
• Billions in hidden borrowing taken without board knowledge
• Forged bank documents and signatures used to secure credit facilities
• Company funds allegedly diverted to other Shetty-controlled entities, including UAE Exchange and Finablr

Shetty has maintained his innocence throughout. His defence team has argued that subordinates, including former CEO Prasanth Manghat, acted without his knowledge or authorisation. Manghat and former financial officer Haidar Abdulrazzaq also face charges.

The restructuring disrupted Abu Dhabi's private hospital market

After NMC shares were suspended from the London Stock Exchange in April 2020, the UK High Court placed the company into administration under Alvarez & Marsal. The restructuring took over a year. Creditors, primarily Middle Eastern and international banks that had extended billions in undisclosed loans, took control of the operating entity through a recovery plan.

NMC's hospitals never closed. Patients continued receiving care throughout the administration. But the collapse froze supplier payments and stalled staff recruitment across the group. Competing operators, particularly Pure Health and Burjeel Holdings, absorbed market share in Abu Dhabi during the years NMC spent in restructuring.

The Department of Health Abu Dhabi (DOH) confronted a practical problem: its largest licensed private operator was technically insolvent. DOH worked with administrators to ensure continuity of care across NMC facilities during the transition, a precedent that has since informed the regulator's approach to financial oversight of large hospital groups.

What the trial means for the market now

The trial carries consequences beyond Shetty's personal liability. UAE regulators and the Abu Dhabi Global Market (ADGM) courts are simultaneously handling civil recovery proceedings. Creditor banks are pursuing asset recovery across multiple jurisdictions. The outcome will test whether the UAE's legal system can deliver accountability in a corporate fraud case of this scale, a question that international investors have tracked since the collapse.

For healthcare operators, the NMC case reshaped how banks underwrite hospital groups in the Gulf. Lenders now require more granular financial disclosure from healthcare borrowers. DOH has tightened financial reporting requirements for large facility operators. The period when a single founder could leverage a hospital chain into billions of undisclosed debt without triggering regulatory flags is over.

The trial is expected to run for several months. A verdict would close one chapter of the largest corporate fraud in UAE history, but financial recovery for creditors owed billions will continue long after the courtroom proceedings end.